Ascletis Pharma Inc. has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 (NCT06972992), involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a placebo, along with four doses of semaglutide (0.5 mg, once weekly). The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.